Accustem Sciences Inc.
Accustem Sciences Inc.
- Market cap
- $7.07M
Your view on ACUT
Overview
What the company does, where it operates, and who runs it.
About Accustem Sciences Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Wendy E. Blosser
- Headquarters
- 5 Penn Plaza, New York City, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Wendy E. Blosser
- Headquarters
- 5 Penn Plaza, New York City, NY, US
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer.
It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Accustem Sciences Inc.. Starting points for Accustem Sciences Inc.: EPS -$0.19, beta 2.38 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Accustem Sciences Inc.. Accustem Sciences Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Accustem Sciences Inc.. Trailing twelve-month EPS for Accustem Sciences Inc. stands at -$0.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Accustem Sciences Inc.. Accustem Sciences Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| CLCSCell Source, Inc. | Healthcare | Biotechnology | $24.5M | ||
| GLABFGemina Laboratories Ltd. | Healthcare | Biotechnology | $3.8M | ||
| GTHPGuided Therapeutics, Inc. | Healthcare | Medical - Devices | $25.1M | ||
| MRESInstitute of Biomedical Research Corp. | Healthcare | Biotechnology | $4.3M | ||
| PPCBPropanc Biopharma Inc. Common Stock | Healthcare | Biotechnology | $1.8M | ||
| QPTFFQuest PharmaTech Inc. | Healthcare | Biotechnology | $2.2M | ||
| SYGGFSynairgen plc | Healthcare | Biotechnology | $11,027 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ENP.AXEntropy Neurodynamics Limited | Healthcare | ASX | — | ||
| ENSCEnsysce Biosciences, Inc. | Healthcare | NASDAQ | $7.0M | ||
| ENTAEnanta Pharmaceuticals, Inc. | Healthcare | NASDAQ | $221.9M | ||
| ENTXEntera Bio Ltd. | Healthcare | NASDAQ | $575.5M | ||
| ENVBEnveric Biosciences, Inc. | Healthcare | NASDAQ | $6.0M | ||
| ENZCEnzolytics Inc. | Healthcare | OTC | $2.0M | ||
| ENZNEnzon Pharmaceuticals, Inc. | Healthcare | OTC | $4.1M | ||
| EPRXEupraxia Pharmaceuticals Inc. | Healthcare | NASDAQ | $390.2M | ||
| EPRX.TOEupraxia Pharmaceuticals Inc. | Healthcare | TSX | $561.0M | ||
| EQEquillium, Inc. | Healthcare | NASDAQ | $87.3M | ||
| ERASErasca, Inc. | Healthcare | NASDAQ | $4.8B | ||
| ERNAErnexa Therapeutics Inc. | Healthcare | NASDAQ | $2.3M | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Accustem Sciences Inc. executives and directors. Shares of Accustem Sciences Inc. have traded between $0.24 and $2.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Accustem Sciences Inc.